Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2026, Vol. 31 ›› Issue (10): 1392-1399.doi: 10.12092/j.issn.1009-2501.2026.10.010
Tianyun YANG(
), Zhihong CHEN(
)
Received:2025-11-30
Revised:2026-01-12
Online:2026-10-26
Published:2026-11-11
CLC Number:
Tianyun YANG, Zhihong CHEN. Progress in the use of rituximab in interstitial lung disease[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(10): 1392-1399.
| 作者 | 时间 | 研究方式 | 患者人数 | 结果 | 随访时间 | 主要终点 | 不良反应 |
| 特发性炎性肌病合并间质性肺病 | |||||||
| Narváez J, et al[ | 2024 | 回顾性 | 28 | 肺功能改善、泼尼松的中位剂量显著减少。需要氧疗的患者中,33%可以停止氧疗 | 6个月 | 肺功能FVC和DLCO改善情况 | 不良反应率28.5%,感染占14% |
| Maher TM, et al[ | 2023 | 随机、对照、前瞻性 | 101 | 环磷酰胺组和RTX组的FVC均较基线有所改善 | 24周 | 与基线相比FVC的变化 | RTX组不良反应略低 |
| Chenjia He, et al[ | 2022 | 荟萃分析 | 35 | 25例患者对治疗有反应 | 1月 | HRCT及肺功能变化 | 37.14%报告了感染 |
| 类风湿关节炎合并间质性肺病 | |||||||
| Md Yusof MY, et al[ | 2017 | 回顾性 | 56 | 56例患者FVC及DLCO均得到改善 | 10年 | 治疗前后FVC及DLCO的变化 | 感染、ILD 进展等 |
| Fui A, et al[ | 2020 | 回顾性 | 14 | 14例患者FVC、FEV1、TLC较基线均有改善 | 1年 | 治疗前后肺功能改善情况 | 未报道 |
| Pugashetti JV, et al[ | 2024 | 回顾性 | 31 | 31例患者FVC及DLCO均改善,且26%患者可停用激素。 | 1年 | 治疗前后肺功能改善情况 | 感染 |
| 系统性硬化症相关性间质性肺病 | |||||||
| Sircar G, et al[ | 2018 | 开放性、随机、对照试验 | 60(随机分为CYC组及RTX组) | RTX组FVC改善而CYC 组降低,mRSS、6分钟 步行测试改善,且副作用更小 | 6个月 | FVC改善情况 | CYC组不良反应更明显 |
| Ebata S, et al[ | 2021 | 随机对照研究 | 48 | 在第24周时FVC保持稳定,而安慰剂组FVC下降 | 2年 | mRSS评分及肺功能改善情况 | 上呼吸道感染多见 |
| 干燥综合征相关性间质性肺病 | |||||||
| Chen MH, et al[ | 2016 | 回顾性研究 | 10 | 症状缓解,DLCO改善,影像学变化稳定。 | 6个月 | 肺功能及胸部CT变化 | 1例非致病性 肺炎 |
Table 1 Summary of major clinical studies on rituximab (RTX) for the treatment of interstitial lung disease (ILD)
| 作者 | 时间 | 研究方式 | 患者人数 | 结果 | 随访时间 | 主要终点 | 不良反应 |
| 特发性炎性肌病合并间质性肺病 | |||||||
| Narváez J, et al[ | 2024 | 回顾性 | 28 | 肺功能改善、泼尼松的中位剂量显著减少。需要氧疗的患者中,33%可以停止氧疗 | 6个月 | 肺功能FVC和DLCO改善情况 | 不良反应率28.5%,感染占14% |
| Maher TM, et al[ | 2023 | 随机、对照、前瞻性 | 101 | 环磷酰胺组和RTX组的FVC均较基线有所改善 | 24周 | 与基线相比FVC的变化 | RTX组不良反应略低 |
| Chenjia He, et al[ | 2022 | 荟萃分析 | 35 | 25例患者对治疗有反应 | 1月 | HRCT及肺功能变化 | 37.14%报告了感染 |
| 类风湿关节炎合并间质性肺病 | |||||||
| Md Yusof MY, et al[ | 2017 | 回顾性 | 56 | 56例患者FVC及DLCO均得到改善 | 10年 | 治疗前后FVC及DLCO的变化 | 感染、ILD 进展等 |
| Fui A, et al[ | 2020 | 回顾性 | 14 | 14例患者FVC、FEV1、TLC较基线均有改善 | 1年 | 治疗前后肺功能改善情况 | 未报道 |
| Pugashetti JV, et al[ | 2024 | 回顾性 | 31 | 31例患者FVC及DLCO均改善,且26%患者可停用激素。 | 1年 | 治疗前后肺功能改善情况 | 感染 |
| 系统性硬化症相关性间质性肺病 | |||||||
| Sircar G, et al[ | 2018 | 开放性、随机、对照试验 | 60(随机分为CYC组及RTX组) | RTX组FVC改善而CYC 组降低,mRSS、6分钟 步行测试改善,且副作用更小 | 6个月 | FVC改善情况 | CYC组不良反应更明显 |
| Ebata S, et al[ | 2021 | 随机对照研究 | 48 | 在第24周时FVC保持稳定,而安慰剂组FVC下降 | 2年 | mRSS评分及肺功能改善情况 | 上呼吸道感染多见 |
| 干燥综合征相关性间质性肺病 | |||||||
| Chen MH, et al[ | 2016 | 回顾性研究 | 10 | 症状缓解,DLCO改善,影像学变化稳定。 | 6个月 | 肺功能及胸部CT变化 | 1例非致病性 肺炎 |
| 1 |
Liu Y, Liu Y, Xu J, et al. Efficacy of rituximab versus cyclophosphamide in connective tissue disease-related interstitial lung disease: a systematic review and meta-analysis[J]. Clin Rheumatol, 2025, 44 (7): 2601- 2610.
doi: 10.1007/s10067-025-07533-6 |
| 2 |
Robles-Perez A, Molina-Molina M. Treatment considerations of lung involvement in rheumatologic disease[J]. Respiration, 2015, 90 (4): 265- 274.
doi: 10.1159/000441238 |
| 3 |
邢楠舒, 张榕. 生物制剂及小分子靶向药物治疗CTD-ILD[J]. 中华临床免疫和变态反应杂志, 2020, 14 (5): 495- 499.
doi: 10.3969/j.issn.1673-8705.2020.05.015 |
| 4 |
Weiner GJ. Rituximab: mechanism of action[J]. Semin Hematol, 2010, 47 (2): 115- 123.
doi: 10.1053/j.seminhematol.2010.01.011 |
| 5 |
Liossis SC, Bounia CA. Treating autoimmune-related interstitial lung disease with B cell depletion[J]. Front Med (Lausanne), 2022, 9, 937561.
doi: 10.3389/fmed.2022.937561 |
| 6 |
Van Meerten T, Hagenbeek A. CD20-targeted therapy: the next generation of antibodies[J]. Semin Hematol, 2010, 47 (2): 199- 210.
doi: 10.1053/j.seminhematol.2010.01.007 |
| 7 |
霍荣秀, 郭乾育, 许珂. 药物治疗结缔组织病相关间质性肺疾病的进展[J]. 中华风湿病学杂志, 2022, 26 (7): 489- 493.
doi: 10.3760/cma.j.cn141217-20210311-00099 |
| 8 |
Thong L, Chawke LJ, Murphy G, et al. Management of myositis associated interstitial lung disease[J]. Rheumatol Int, 2023, 43 (7): 1209- 1220.
doi: 10.1007/s00296-023-05336-z |
| 9 |
Hallowell RW, Danoff SK. Diagnosis and management of myositis-associated lung disease[J]. Chest, 2023, 163 (6): 1476- 1491.
doi: 10.1016/j.chest.2023.01.031 |
| 10 |
Marie I, Hatron PY, Dominique S, et al. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients[J]. Arthritis Rheum, 2011, 63 (11): 3439- 3447.
doi: 10.1002/art.30513 |
| 11 |
Marie I, Josse S, Hatron PY, et al. Interstitial lung disease in anti-Jo1 patients with antisynthetase syndrome[J]. Arthritis Care Res (Hoboken), 2013, 65 (5): 800- 808.
doi: 10.1002/acr.21895 |
| 12 |
Yu KH, Wu YJ, Kuo CF, et al. Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases[J]. Clin Rheumatol, 2011, 30 (12): 1595- 1601.
doi: 10.1007/s10067-011-1840-0 |
| 13 |
Sugiyama Y, Yoshimi R, Tamura M, et al. The predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial lung disease[J]. Arthritis Res Ther, 2018, 20 (1): 7.
doi: 10.1186/s13075-017-1506-7 |
| 14 |
Narváez J, Cañadillas E, Castellví I, et al. Rituximab in the treatment of progressive interstitial lung disease associated with the antisynthetase syndrome[J]. Arthritis Res Ther, 2024, 26 (1): 122.
doi: 10.1186/s13075-024-03353-2 |
| 15 |
Maher TM, Tudor VA, Saunders P, et al. RECITAL Investigators. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial[J]. Lancet Respir Med, 2023, 11 (1): 45- 54.
doi: 10.1016/S2213-2600(22)00359-9 |
| 16 |
Kouranloo K, Dey M, Elwell H, et al. Management and outcomes of interstitial lung disease associated with anti-synthetase syndrome: a systematic literature review[J]. Rheumatology (Oxford), 2025, 64 (1): 45- 55.
doi: 10.1093/rheumatology/keae403 |
| 17 |
Fujikawa K, Kawakami A, Kaji K, et al. Association of distinct clinical subsets with myositis-specific autoantibodies towards anti-155/140-kDa polypeptides, anti-140-kDa polypeptides, and anti-aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single-centre, cross-sectional study[J]. Scand J Rheumatol, 2009, 38 (4): 263- 267.
doi: 10.1080/03009740802687455 |
| 18 |
He C, Li W, Xie Q, et al. Rituximab in the treatment of interstitial lung diseases related to anti-melanoma differentiation-associated gene 5 dermatomyositis: a systematic review[J]. Front Immunol, 2022, 12, 820163.
doi: 10.3389/fimmu.2021.820163 |
| 19 | Nascimento J, Tenazinha C, Campanilho-Marques R, et al. Rituximab in the treatment of anti-MDA-5 dermatomyositis-associated interstitial lung disease: a case-based literature review[J]. ARP Rheumatol, 2022, 1 (2): 168- 173. |
| 20 |
Dai Y, Wang W, Yu Y, et al. Rheumatoid arthritis-associated interstitial lung disease: an overview of epidemiology, pathogenesis and management[J]. Clin Rheumatol, 2021, 40 (4): 1211- 1220.
doi: 10.1007/s10067-020-05320-z |
| 21 |
Atkins SR, Turesson C, Myers JL, et al. Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia[J]. Arthritis Rheum, 2006, 54 (2): 635- 641.
doi: 10.1002/art.21758 |
| 22 |
Md Yusof MY, Kabia A, Darby M, et al. Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre[J]. Rheumatology (Oxford), 2017, 56 (8): 1348- 1357.
doi: 10.1093/rheumatology/kex072 |
| 23 |
Fui A, Bergantini L, Selvi E, et al. Rituximab therapy in interstitial lung disease associated with rheumatoid arthritis[J]. Intern Med J, 2020, 50 (3): 330- 336.
doi: 10.1111/imj.14306 |
| 24 |
Pugashetti JV, Lee JS. Overview of rheumatoid arthritis-associated interstitial lung disease and its treatment[J]. Semin Respir Crit Care Med, 2024, 45 (3): 329- 341.
doi: 10.1055/s-0044-1782218 |
| 25 |
Kelly CA, Nisar M, Arthanari S, et al. Rheumatoid arthritis related interstitial lung disease-improving outcomes over 25 years: a large multicentre UK study[J]. Rheumatology (Oxford), 2021, 60 (4): 1882- 1890.
doi: 10.1093/rheumatology/keaa577 |
| 26 | Holroyd CR, Seth R, Bukhari M, et al. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis-Executive summary[J]. Rheumatology (Oxford), 2019, 58 (2): 220- 226. |
| 27 |
Fassio A, Sebastiani M, Pollastri F, et al. Updated systematic literature review and meta-analysis to inform the Italian Society of Rheumatology recommendations on the treatment of rheumatoid arthritis-associated interstitial lung disease[J]. Autoimmun Rev, 2025, 24 (12): 103922.
doi: 10.1016/j.autrev.2025.103922 |
| 28 |
Volkmann ER, Andréasson K, Smith V. Systemic sclerosis[J]. Lancet, 2023, 401 (10373): 304- 318.
doi: 10.1016/S0140-6736(22)01692-0 |
| 29 |
Sircar G, Goswami RP, Sircar D, et al. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial[J]. Rheumatology (Oxford), 2018, 57 (12): 2106- 2113.
doi: 10.1093/rheumatology/key213 |
| 30 | Ebata S, Yoshizaki A, Oba K, et al. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial[J]. Lancet Rheumatol, 2021, 3 (7): e489e497. |
| 31 |
中国初级卫生保健基金会风湿免疫学分会干燥综合征和IgG4相关性疾病专委会, 系统性红斑狼疮专委会. 利妥昔单抗治疗风湿免疫病中国专家共识(2024 版)[J]. 中华风湿病学杂志, 2024, 28 (8): 521- 537.
doi: 10.3760/cma.j.cn141217-20240604-00179 |
| 32 |
Negrini S, Emmi G, Greco M, et al. Sjögren's syndrome: a systemic autoimmune disease[J]. Clin Exp Med, 2022, 22 (1): 9- 25.
doi: 10.1007/s10238-021-00728-6 |
| 33 |
Pontarini E, Sciacca E, Chowdhury F, et al. Serum and tissue biomarkers associated with composite of relevant endpoints for Sjögren syndrome (CRESS) and Sjögren tool for assessing response (STAR) to B cell-targeted therapy in the trial of anti-B cell therapy in patients with primary Sjögren syndrome (TRACTISS)[J]. Arthritis Rheumatol, 2024, 76 (5): 763- 776.
doi: 10.1002/art.42772 |
| 34 |
Manfredi A, Sebastiani M, Cerri S, et al. Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement[J]. Clin Rheumatol, 2017, 36 (6): 1261- 1268.
doi: 10.1007/s10067-017-3601-1 |
| 35 |
Lin W, Xin Z, Zhang J, et al. Interstitial lung disease in primary Sjögren's syndrome[J]. BMC Pulm Med, 2022, 22 (1): 73.
doi: 10.1186/s12890-022-01868-5 |
| 36 |
Vacchi C, Sebastiani M, Cassone G, et al. Therapeutic options for the treatment of interstitial lung disease related to connective tissue diseases. a narrative review[J]. J Clin Med, 2020, 9 (2): 407.
doi: 10.3390/jcm9020407 |
| 37 |
Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, et al. Topical and systemic medications for the treatment of primary Sjögren's syndrome[J]. Nat Rev Rheumatol, 2012, 8 (7): 399- 411.
doi: 10.1038/nrrheum.2012.53 |
| 38 |
Saraux A, Pers JO, Devauchelle-Pensec V. Treatment of primary Sjögren syndrome[J]. Nat Rev Rheumatol, 2016, 12 (8): 456- 471.
doi: 10.1038/nrrheum.2016.100 |
| 39 |
Verstappen GM, Van Nimwegen JF, Vissink A, et al. The value of rituximab treatment in primary Sjögren's syndrome[J]. Clin Immunol, 2017, 182, 62- 71.
doi: 10.1016/j.clim.2017.05.002 |
| 40 | Chen MH, Chen CK, Chou HP, et al. Rituximab therapy in primary Sjögren's syndrome with interstitial lung disease: a retrospective cohort study[J]. Clin Exp Rheumatol, 2016, 34 (6): 1077- 1084. |
| 41 |
Gupta S, Ferrada MA, Hasni SA. Pulmonary manifestations of primary Sjögren's syndrome: underlying immunological mechanisms, clinical presentation, and management[J]. Front Immunol, 2019, 10, 1327.
doi: 10.3389/fimmu.2019.01327 |
| 42 | Price EJ, Rauz S, Tappuni AR, et al. The british society for rheumatology guideline for the management of adults with primary Sjögren's syndrome[J]. Rheumatology (Oxford), 2017, 56 (10): e24- e48. |
| 43 |
Reina D, Roig Vilaseca D, Torrente-Segarra V, et al. Sjögren's syndrome-associated interstitial lung disease: a multicenter study[J]. Reumatol Clin, 2016, 12 (4): 201- 205.
doi: 10.1016/j.reuma.2015.09.003 |
| 44 |
Enomoto Y, Takemura T, Hagiwara E, et al. Prognostic factors in interstitial lung disease associated with primary Sjögren's syndrome: a retrospective analysis of 33 pathologically-proven cases[J]. PLoS One, 2013, 8 (9): e73774.
doi: 10.1371/journal.pone.0073774 |
| 45 |
Amarnani R, Yeoh SA, Denneny EK, et al. Lupus and the lungs: the assessment and management of pulmonary manifestations of systemic lupus erythematosus[J]. Front Med (Lausanne), 2021, 7, 610257.
doi: 10.3389/fmed.2020.610257 |
| 46 |
Benham H, Garske L, Vecchio P, et al. Successful treatment of shrinking lung syndrome with rituximab in a patient with systemic lupus erythematosus[J]. J Clin Rheumatol, 2010, 16 (2): 68- 70.
doi: 10.1097/RHU.0b013e3181d0757f |
| 47 |
Langenskiöld E, Bonetti A, Fitting JW, et al. Shrinking lung syndrome successfully treated with rituximab and cyclophosphamide[J]. Respiration, 2012, 84 (2): 144- 149.
doi: 10.1159/000334947 |
| 48 |
Arulkumaran N, Periselneris N, Gaskin G, et al. Interstitial lung disease and ANCA-associated vasculitis: a retrospective observational cohort study[J]. Rheumatology (Oxford), 2011, 50 (11): 2035- 2043.
doi: 10.1093/rheumatology/ker236 |
| 49 |
Comarmond C, Crestani B, Tazi A, et al. Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literature[J]. Medicine (Baltimore), 2014, 93 (24): 340- 349.
doi: 10.1097/MD.0000000000000217 |
| 50 | Sebastiani M, Manfredi A, Vacchi C, et al. Epidemiology and management of interstitial lung disease in ANCA-associated vasculitis[J]. Clin Exp Rheumatol, 2020, 124 (2): 221- 231. |
| 51 |
Hozumi H, Enomoto N, Oyama Y, et al. Clinical implication of proteinase-3-antineutrophil cytoplasmic antibody in patients with idiopathic interstitial pneumonias[J]. Lung, 2016, 194 (2): 235- 242.
doi: 10.1007/s00408-016-9851-x |
| 52 |
Fernandez Casares M, Gonzalez A, Fielli M, et al. Microscopic polyangiitis associated with pulmonary fibrosis[J]. Clin Rheumatol, 2015, 34 (7): 1273- 1277.
doi: 10.1007/s10067-014-2676-1 |
| 53 | Streho M, Sable-Fourtassou R, Brion MC, et al. Churg-strauss syndrome and pulmonary fibrosis: an unusual association [J]. Presse Med, 2006, 35(9 Pt 1): 1259-1262. |
| 54 |
Maillet T, Goletto T, Beltramo G, et al. French Vasculitis Study Group (FVSG). Usual interstitial pneumonia in ANCA-associated vasculitis: a poor prognostic factor[J]. J Autoimmun, 2020, 106, 102338.
doi: 10.1016/j.jaut.2019.102338 |
| 55 |
Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis[J]. Ann Rheum Dis, 2016, 75 (9): 1583- 1594.
doi: 10.1136/annrheumdis-2016-209133 |
| 56 |
Morisset J, Lee JS. New trajectories in the treatment of interstitial lung disease: treat the disease or treat the underlying pattern[J]. Curr Opin Pulm Med, 2019, 25 (5): 442- 449.
doi: 10.1097/MCP.0000000000000600 |
| 57 |
Robles-Perez A, Dorca J, Castellví I, et al. Rituximab effect in severe progressive connective tissue disease-related lung disease: preliminary data[J]. Rheumatol Int, 2020, 40 (5): 719- 726.
doi: 10.1007/s00296-020-04545-0 |
| 58 | Barba T, Mainbourg S, Nasser M, et al. Lung diseases in inflammatory myopathies[J]. Semin Respir Crit Care Med, 2019, 40 (2): 255- 270. |
| 59 |
Romero-Bueno F, Diaz Del Campo P, Trallero-Araguás E, et al. MEDRA5 (Spanish MDA-5 Register) group. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease[J]. Semin Arthritis Rheum, 2020, 50 (4): 776- 790.
doi: 10.1016/j.semarthrit.2020.03.007 |
| 60 |
Tony HP, Burmester G, Schulze-Koops H, et al. GRAID investigators. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)[J]. Arthritis Res Ther, 2011, 13 (3): R75.
doi: 10.1186/ar3337 |
| 61 |
Kerschbaumer A, Sepriano A, Bergstra SA, et al. Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis[J]. Ann Rheum Dis, 2023, 82 (1): 95- 106.
doi: 10.1136/ard-2022-223365 |
| 62 |
Kari JA, El-Morshedy SM, El-Desoky S, et al. Rituximab for refractory cases of childhood nephrotic syndrome[J]. Pediatr Nephrol, 2011, 26 (5): 733- 737.
doi: 10.1007/s00467-011-1778-0 |
| 63 |
Chari R, Abdelghany Y, Purcell M, et al. Rituximab induced lung injury[J]. BMC Pulm Med, 2025, 25 (1): 359.
doi: 10.1186/s12890-025-03802-x |
| 64 |
Liu X, Hong XN, Gu YJ, et al. Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma[J]. Leuk Lymphoma, 2008, 49 (9): 1778- 1783.
doi: 10.1080/10428190802270886 |
| 65 |
Wagner SA, Mehta AC, Laber DA. Rituximab-induced interstitial lung disease[J]. Am J Hematol, 2007, 82 (10): 916- 919.
doi: 10.1002/ajh.20910 |
| 66 |
Zamfir AS, Marinca MV, Zamfir CL, et al. Rituximab-induced interstitial lung disease: a possible underestimated complication-a systematic review[J]. Cancers (Basel), 2025, 17 (23): 3786.
doi: 10.3390/cancers17233786 |
| 67 |
Alho HS, Maasilta PK, Harjula AL, et al. Tumor necrosis factor-alpha in a porcine bronchial model of obliterative bronchiolitis[J]. Transplantation, 2003, 76 (3): 516- 523.
doi: 10.1097/01.TP.0000074700.30536.76 |
| [1] | WU Shan, YU Qi, YANG Qin, WANG Wenjing, ZHANG Yangyang, LIU Yan, YANG Yanlang. Comparing the efficacy and safety of cyclophosphamide and rituximab in idiopathic membranous nephropathy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(5): 657-664. |
| [2] | LIU Shuang, JIANG Hanchun, WU Jingjing, ZHAO Rongsheng. Umbrella review of the efficacy and safety of monoclonal antibodies in the treatment of thyroid-associated ophthalmopathy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(7): 735-743. |
| [3] | LI Mengxue, HE Jie, YU Xiaxia, HU Linlin, SHAO Hua. Research progress in population pharmacokinetics of rituximab [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 468-474. |
| [4] | HOU Liping, YAN Yuyang, LI Li, YANG Jianbo, OUYANG Dongsheng. Development of quantitative analysis methods of Rituximab and it's biosimilar in biological samples [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 98-104. |
| [5] | WANG Xiao, YUE Hongmei, WANG Ruoli, SUN Jinying, LI Le, LIU Ruichao. Research Progress of Pirfenidone for connective tissue disease-associated interstitial lung diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 584-590. |
| [6] | YU Shuyuan, ZHENG Lin, HAN Fei. Pathogenesis and treatment progress of antineutrophil cytoplasmic antibody-associated vasculitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 235-240. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||